Molecular Imaging Corporation Replaces Competitor at Kaweah Delta Health Care District; California Hospital Cites Service as Reason for Change

Business Wire, June 17, 2004

SAN DIEGO -- Molecular Imaging Corporation ("MIC" or the "Company") (OTCBB: MLRI), a leading provider of molecular imaging services to healthcare entities in the U.S., announced that it has entered into an agreement with Kaweah Delta Health Care District, to provide Positron Emission Tomography ("PET") imaging services at its facility in the California Central Valley.

According to Mr. Gordon Ah Tye, Director, Imaging Services, for the Visalia, California hospital, and former President of the American Healthcare Radiology Administrators, "Molecular Imaging partnered with us fully. They are very customer focused."

Mr. Ah Tye added, "After working diligently on details preparing for us to bring PET services back on line with the sales representative, MIC brought in the balance of their team to help us start up. I was so impressed by the entire group of MIC representatives. Their software consultant delivered, installed, and provided applications for our radiologists the week prior to start-up, which gave our radiologists a sense of confidence about MIC and what we had in store. Everything on the software side went very smoothly, from fusion integration to connecting to our internal system. As a final detail, MIC even brought in their scheduling specialist, who worked directly with our clerical staff to set up guidelines as to what to expect from MIC and what needed to be done from their perspectives.

"Needless to say, I have been very impressed with MIC's staff and their ability to deliver the services we needed. After six weeks, we greatly exceeded the start up volumes that we had projected, and our referring physicians and radiologists are extremely pleased with the quality, expertise, and professionalism that Molecular Imaging Corporation has provided."

"At the end of the day," said Paul Crowe, CEO of Molecular Imaging Corporation, "what we sell is service, and in that regard we pride ourselves on exceeding the expectations of our customers. We measure customer satisfaction at each stage of a relationship, knowing that the ultimate goal is a long term partnership with each and every customer.

"We are very pleased to have been selected as a business partner by Kaweah Delta, and are genuinely excited about the opportunity to help them provide state of the art technology to their central California community. "

About Kaweah Delta

Kaweah Delta Health Care District, a family of health care facilities in the San Joaquin Valley, provides a full spectrum of health care services utilizing an array of cutting-edge medical technology. The District consists of four campuses, including the largest acute care hospital in Tulare County. Kaweah Delta offers a broad range of services including cardiac services, state-of-the-art cancer care, sleep disorders and vascular labs, specialized orthopedics, comprehensive rehabilitation, and mental health services. Additionally, Kaweah Delta is home to a nationally recognized cardiac program. Partnered with Starr-Wood Cardiac Group, its Cardiac Services Program captured recognition as one of the Top 100 Hospitals for cardiovascular services by HCIA-Sachs; one of only six hospitals in the state of California to be recognized.

About Molecular Imaging Corporation

Molecular Imaging Corporation is a leading national service provider of Positron Emission Tomography ("PET") diagnostic imaging services. PET is a 3-Dimensional Full Body molecular imaging procedure used to diagnose, stage and assess treatment outcomes for many cancers, cardiovascular disease and neurological disorders. The Company operates both mobile and permanent (fixed) PET imaging technologies for hospitals, diagnostic imaging centers and physician group practices across the U.S. The Company's clinical web site, www.PETadvances.com, addresses questions about the various cancers and how molecular imaging can assist and benefit physicians and their patients. The Company's commercial web site, (www.molecularimagingcorp.com), addresses questions about our commercial services and investor relations.

Certain statements contained in this press release are "forward-looking statements" within the meaning of applicable federal securities laws, including, without limitation, anything relating or referring to future financial results and plans for future business development activities, and are thus prospective. Forward-looking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified based on current expectations. Such risks and uncertainties include, without limitation, the risks and uncertainties set forth from time to time in reports filed by the company with the Securities and Exchange Commission. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Consequently, future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward the forward-looking statements contained herein. The companies undertake no obligation to publicly release statements made to reflect events or circumstances after the date hereof.